Skip to Main Content

In her latest bid to address prescription drug prices, U.S. Sen. Elizabeth Warren (D-Mass.) is urging the U.S. Federal Trade Commission to “closely scrutinize” two pending pharmaceutical company mergers over concerns that “rampant consolidation” will drive up costs for consumers.

One deal involves Amgen, which plans to pay $28.7 billion to acquire Horizon Therapeutics, a company that markets treatments for autoimmune disorders and recently generated takeover interest from a few large drug companies. The other deal involves two companies that have been involved in the opioid business; Indivior plans to buy Opiant for $145 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment